[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy].

Abstract

The aim of the investigation was twofold: to study the effect of lovastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alone and in combination with other lipid lowering drugs in an open 48 week single centre study, and to study if lipid lowering drugs influence adherence to diet in adult patients with familial hypercholesterolemia. Lovastatin monotherapy (80 mg daily) for 12 weeks reduced serum cholesterol, LDL-cholesterol and triglycerides levels by 36%, 44% and 24% respectively. HDL-cholesterol level was increased by 12%. The addition of 16 g cholestyramine daily further increased the reduction of total cholesterol and LDL-cholesterol levels by 17% and 24% respectively. Addition of 1 g probucol daily decreased total cholesterol, LDL-cholesterol and HDL-cholesterol levels by 9%, 5% and 27% respectively. Addition of omega-3-fatty acids (3.6 g daily) reduced total cholesterol, LDL-cholesterol and triglycerides levels by 10%, 12% and 20% respectively. Administration of potent lipid lowering agents did not influence adherence to a diet with a mean daily fat energy of 21% (CI: 20-22), cholesterol of 177 mg (CI: 157-196) and P/S ratio of 0.75 (CI: 0.66-0.84). A significant increase in liver enzymes was recorded in only one patient. One patient was withdrawn from the study because of myositis.

• Authors: M Stugaard, I Wiig, H Lund, L Ose, J Norseth
• Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (Tidsskr Nor Laegeforen) Vol. 112 Issue 20 Pg. 2642-6 (Aug 30 1992) ISSN: 0029-2001 [Print] Norway
• Vernacular Title: Familiaer hyperkolesterolemi--intensiv kostbehandling i kombinasjon med medikamentell behandling.
• PMID: 1412289 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Hypolipidemic Agents
• Cholestyramine Resin
• Lovastatin

Topics

• Adolescent
• Adult
• Aged
• Cholestyramine Resin (adverse effects, therapeutic use)
• Drug Evaluation
• Drug Therapy, Combination
• Humans
• Hyperlipoproteinemia Type II (blood, diet therapy, drug therapy)
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Lovastatin (adverse effects, therapeutic use)
• Middle Aged